title: Molecular insights on pathogenic effects of mutations causing phosphoglycerate kinase deficiency.
abstract: Phosphoglycerate kinase (PGK) catalyzes an important ATP-generating step in glycolysis. PGK1 deficiency is an uncommon X-linked inherited disorder, generally characterized by various combinations of non-spherocytic hemolytic anemia, neurological dysfunctions, and myopathies. Patients rarely exhibit all three clinical features. To provide a molecular framework to the different pathological manifestations, all known mutations were reviewed and 16 mutant enzymes, obtained as recombinant forms, were functionally and structurally characterized. Most mutations heavily affect thermal stability and to a different extent catalytic efficiency, in line with the remarkably low PGK activity clinically observed in the patients. Mutations grossly impairing protein stability, but moderately affecting kinetic properties (p.I47N, p.L89P, p.C316R, p.S320N, and p.A354P) present the most homogeneous correlation with the clinical phenotype. Patients carrying these mutations display hemolytic anemia and neurological disorders, and,except for p.A354P variant, no myopaty. Variants highly perturbed in both catalytic efficiency (p.G158V, p.D164V, p.K191del, D285V, p.D315N, and p.T378P) and heat stability (all, but p.T378P) result to be mainly associated with myopathy alone. Finally, mutations faintly affecting molecular properties (p.R206P, p.E252A, p.I253T, p.V266M, and p.D268N) correlate with a wide spectrum of clinical symptoms. These are the first studies that correlate the clinical symptoms with the molecular properties of the mutant enzymes. All findings indicate that the different clinical manifestations associated with PGK1 deficiency chiefly depend on the distinctive type of perturbations caused by mutations in the PGK1 gene, highlighting the need for determination of the molecular properties of PGK variants to assist in prognosis and genetic counseling. However, the clinical symptoms can not be understood only on the bases of molecular properties of the mutant enzyme. Different (environmental, metabolic, genetic and/or epigenetic) intervening factors can contribute toward the expression of PGK deficient clinical phenotypes.
authors.affiliation: Dipartimento di Biologia e Biotecnologie L Spallanzani, Università degli Studi di Pavia, Pavia, Italy.
authors.forename: Laurent R
authors.initials: LR
authors.lastname: Chiarelli
authors.forename: Simone M
authors.initials: SM
authors.lastname: Morera
authors.forename: Paola
authors.initials: P
authors.lastname: Bianchi
authors.forename: Elisa
authors.initials: E
authors.lastname: Fermo
authors.forename: Alberto
authors.initials: A
authors.lastname: Zanella
authors.forename: Alessandro
authors.initials: A
authors.lastname: Galizzi
authors.forename: Giovanna
authors.initials: G
authors.lastname: Valentini
mesh_terms: D000743:Anemia, Hemolytic / Q000235:genetics; D006801:Humans; D007700:Kinetics; D050505:Mutant Proteins; D009154:Mutation; D009422:Nervous System Diseases / Q000235:genetics; D010641:Phenotype; D010735:Phosphoglycerate Kinase / Q000172:deficiency* / Q000235:genetics; D055550:Protein Stability
chemical_list: D050505:Mutant Proteins; D010735:Phosphoglycerate Kinase